Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc.

Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage life sciences company developing central nervous system therapeutics designed to overcome the blood-brain barrier. The company's pipeline includes multiple assets, with NEO100 being a patented, pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility. This coverage initiation matters because it brings institutional attention to a company addressing one of neuroscience's most significant challenges: delivering therapeutics effectively to the brain.

NeOnc's intranasal administration strategy represents a potentially transformative approach to central nervous system drug delivery. By accessing the brain via olfactory and trigeminal pathways, this non-invasive route could improve patient adherence and enable more direct delivery compared to traditional methods. The implications of this technology extend beyond NeOnc's specific pipeline, potentially establishing new standards for how neurological conditions are treated. Stonegate views NTHI as a differentiated platform, supported by favorable tolerability with prolonged dosing and multiple near-term catalysts as the program advances.

The timing of this coverage initiation coincides with several important developments for NeOnc. Positive Phase 1/2a results for NEO100 were announced in December, providing early validation of the company's approach. More significantly, the NEO100 Phase 2a top-line readout is expected in Mid-2026, representing a major milestone that could validate both the compound's efficacy and the intranasal delivery platform. Additionally, the closing and funding of the Quazar Investment is expected in the near-term, which would provide additional resources to advance the company's clinical programs.

This coverage matters because it signals growing institutional recognition of NeOnc's potential to address significant unmet medical needs in neurology and oncology. The blood-brain barrier has long been a major obstacle in developing effective treatments for conditions ranging from brain tumors to neurodegenerative diseases. NeOnc's approach, if successful, could enable more effective delivery of existing and new therapeutics to the central nervous system. The company's progress toward its 2026 readout represents a critical inflection point that could significantly impact both patient care and the broader field of neurological therapeutics.

For more information about Stonegate Capital Partners, visit https://www.stonegateinc.com. The firm is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. The initiation of coverage on NeOnc reflects Stonegate's assessment of the company's potential value and the importance of its technology platform in addressing significant challenges in drug delivery and neurological treatment.